Cardiovascular Effects of Hypothyroidism

Hemodynamic Changes

• Bradycardia is one of the most common cardiovascular manifestations of hypothyroidism 1
• Systemic vascular resistance can increase by as much as 50% 2
• Diastolic relaxation and filling are significantly slowed 2
• Low cardiac output results from the combination of bradycardia, decreased ventricular filling, and decreased cardiac contractility 2
• Mild hypertension, particularly diastolic hypertension, is common due to increased peripheral resistance 2

Structural and Functional Cardiac Changes

• Hypothyroidism promotes myocardial fibrosis by stimulating fibroblasts 3
• Chronic hypothyroidism leads to loss of coronary arterioles, impaired blood flow, and maladaptive changes in myocyte shape 4
• Pericardial effusions and nonpitting edema (myxedema) can occur in severe, long-standing hypothyroidism 2

Clinical Manifestations and Heart Failure Risk

• Despite significant hemodynamic changes, clinical heart failure is relatively rare in hypothyroidism because cardiac output is usually sufficient to meet the lowered systemic metabolic demands 2
• Dilated cardiomyopathy (DCM) is not a characteristic feature of hypothyroidism, but case reports exist of DCM improving with thyroid hormone replacement 2

Treatment Considerations

• Thyroid function tests are recommended in all patients presenting with heart failure due to the potential contribution of thyroid dysfunction 2

Cardiac Manifestations of Hypothyroidism

Association with Arrhythmias and Cardiac Symptoms

• Hypothyroidism is associated with an increased risk of atrial fibrillation, particularly in elderly patients, according to the American Heart Association 5
• Overtreatment with levothyroxine can cause angina and arrhythmias, as stated by the American College of Cardiology, with possible adverse effects on the cardiovascular system, including angina, arrhythmia, and increased cardiac wall thickness 6, 7

Management and Treatment

• Thyroid hormone replacement is the cornerstone of treatment for hypothyroidism-induced cardiac manifestations, and the Endocrine Society recommends initiate levothyroxine replacement therapy for documented hypothyroidism with cardiac symptoms 6, 7
• The American College of Cardiology suggests that ventricular arrhythmias typically resolve after stabilization of thyroid hormone levels, and coronary artery bypass can be performed safely despite hypothyroidism without requiring full thyroid replacement preoperatively 6, 7

Thyroxine Replacement in Subclinical Hypothyroidism with Cardiac Disease

Key Decision Points

Evidence Supporting Treatment

• The American Medical Association recommends that treatment must be initiated at low doses in patients with cardiac disease, as minimal TSH elevations may not require dosage adjustment in patients who feel well, particularly those with arrhythmias or other cardiac disorders 8
• The European Heart Journal states that atrial fibrillation from thyroid overtreatment would be particularly problematic in mitral stenosis, and tachycardia reduces diastolic filling time, worsening the hemodynamic consequences of mitral stenosis 9
• The American Medical Association supports treatment when TSH >10 mIU/L universally, and at TSH 5-10 mIU/L in symptomatic patients or those with cardiac disease where untreated hypothyroidism contributes to cardiac dysfunction 8, 10

Critical Safety Considerations in Cardiac Disease

• The American Medical Association explicitly states that already-treated patients with minimal elevations may not require dosage adjustment, but this statement does not apply to untreated patients with TSH of 8 mIU/L 8

Specific Approach for This Patient

• The American Medical Association recommends aiming for TSH in the range of 2.5-5.0 mIU/L initially, rather than aggressive normalization to <2.5 mIU/L, and in elderly patients or those with significant cardiac disease, maintaining TSH in the upper half of the reference range is acceptable 8

Hypothyroidism and Hypertension Management

Diagnosis and Screening

• The American College of Cardiology recommends measuring thyroid-stimulating hormone (TSH) in all newly diagnosed hypertensive patients as part of basic laboratory testing to detect hypothyroidism and hyperthyroidism, both of which are remediable causes of hypertension 11

Treatment and Reversibility

• The American College of Cardiology guidelines support the idea that treatment with levothyroxine can normalize blood pressure in patients with hypothyroid-induced hypertension, with the guideline society recommending screening and treatment as part of hypertension management 11

Hypothyroidism and Heart Failure

Introduction to Hypothyroidism and Heart Failure

• The American College of Cardiology/American Heart Association guidelines explicitly list endocrine abnormalities, including hypothyroidism, as common precipitants of acute decompensated heart failure, and restoration of normal thyroid function may reverse abnormal cardiovascular function in patients with congestive heart failure 12

Clinical Impact and Treatment Approach

• Restoration of normal thyroid function may reverse abnormal cardiovascular function in patients with congestive heart failure, according to the American College of Cardiology 12
• Hypothyroidism should be identified and treated in all patients with congestive heart failure, as it is a recognized precipitant of acute decompensated heart failure, and treatment with levothyroxine can improve prognosis and prevent worsening of cardiovascular function 12
• The American College of Cardiology recommends considering hypothyroidism as a reversible cause of heart failure decompensation, particularly when other precipitants are not evident, and screening for hypothyroidism is important in patients treated with amiodarone 12

Management of Hypothyroidism‑Related Cardiac Rhythm Abnormalities

Identification of Hypothyroidism as a Reversible Cause

• The 2018 ACC/AHA/HRS guidelines list hypothyroidism as a potentially reversible cause of sinus node dysfunction and bradycardia, warranting evaluation for thyroid status in new‑onset rhythm disturbances. [13][14]

Diagnostic Evaluation

Symptom‑Rhythm Correlation

• In patients presenting with syncope, presyncope, light‑headedness, fatigue, or exertional dyspnea, clinicians should document the temporal relationship between these symptoms and documented bradycardia using ECG, telemetry, or ambulatory monitoring. [13][14]

Specific Rhythm Abnormalities to Assess

• Evaluate for sinus bradycardia, sinus pauses, chronotropic incompetence, and conduction blocks as the typical arrhythmic manifestations of hypothyroidism. [13][14]

Exclusion of Other Reversible Factors

• Review concomitant medications (e.g., β‑blockers, calcium‑channel blockers, digoxin, anti‑arrhythmics, lithium) that can exacerbate bradycardia. 13
• Check serum electrolytes (potassium, magnesium), rule out acute myocardial infarction, and assess for sleep‑disordered breathing as additional reversible contributors. 13

Initial and Acute Treatment

Thyroid Hormone Replacement (First‑Line)

• Initiate levothyroxine therapy as the primary treatment for symptomatic bradycardia or rhythm disturbances in patients with confirmed hypothyroidism. 14
• Cardiovascular rhythm abnormalities generally improve and often resolve after restoration of euthyroidism with appropriate levothyroxine dosing. 14

Acute Stabilization (When Hemodynamically Unstable)

• For symptomatic bradycardia with hemodynamic compromise, administer atropine or a β‑agonist while simultaneously beginning thyroid hormone replacement. 13
• Reserve temporary transvenous pacing for severe, refractory bradycardia that does not respond to pharmacologic measures. 13
• The majority of hypothyroidism‑related bradycardia cases are clinically stable and do not require emergent pacing. [13][14]

Permanent Pacing Considerations

Situations to Avoid Permanent Pacemaker Implantation

• Do not implant a permanent pacemaker for bradycardia secondary to hypothyroidism until levothyroxine therapy has been optimized and sufficient time (typically ≥ 3 months) has been allowed for rhythm recovery. [13][14]
• Asymptomatic or minimally symptomatic patients with documented bradycardia should not receive permanent pacing. 14
• Permanent pacing is inappropriate when symptoms occur without objective documentation of bradycardia. 14

Indications for Permanent Pacing (After Thyroid Optimization)

• Consider permanent pacing only if symptomatic bradycardia persists despite confirmed euthyroid status and an adequate observation period. [13][14]
• Persistent symptoms must be correlated with documented bradycardia after thyroid correction before proceeding to permanent pacing. [13][14]

Common Pitfalls

• The most frequent error is premature implantation of a permanent pacemaker before adequate treatment of hypothyroidism. [13][14]
• Unnecessary pacemaker implantation exposes patients to procedural risks and long‑term lead‑related complications that are avoidable when the arrhythmia is reversible. 14

Monitoring and Follow‑Up

• Repeat ECG and rhythm assessment 6–12 weeks after initiating levothyroxine to verify resolution of arrhythmia. 14
• Re‑evaluate symptoms and their association with any persistent rhythm abnormality only after thyroid function has normalized. [13][14]
• If bradycardia and related symptoms continue despite documented euthyroidism for at least 3 months, proceed with electrophysiology study or consider permanent pacing. [13][14]